Last reviewed 2026-04-23 · How we verify

HRS-8080

HRS-8080 is an investigational anti-cancer agent being developed by Henan Cancer Hospital, currently in phase 3 clinical trials.

HRS-8080 is an investigational anti-cancer agent being developed by Henan Cancer Hospital, currently in phase 3 clinical trials. Used for Cancer (specific indication unknown).

At a glance

Mechanism of action

Limited public information is available on the specific molecular mechanism of HRS-8080. As a phase 3 oncology candidate from a Chinese cancer center, it is likely a targeted therapy or immunotherapy, but the exact target and mechanism require access to clinical trial registries or company disclosures for confirmation.

Approved indications

• Cancer (specific indication unknown)

Common side effects

No common side effects on file.

Key clinical trials

• A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (PHASE3)
• A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer (PHASE3)
• A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer (PHASE1, PHASE2)
• A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (PHASE1, PHASE2)
• A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer (PHASE3)
• A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants (PHASE1)
• Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer (PHASE1, PHASE2)
• A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.